Kisspeptin analog C6 elicits greater tachyphylaxis and gene activation than Kp-10 and Kp-54
Background
The neuropeptide kisspeptin (Kp) and its receptor (KISS1R, also known as GPR54) are critical regulators of the hypothalamic-pituitary-gonadal (HPG) axis, making them attractive therapeutic targets for reproductive disorders and other medical conditions. Endogenous agonists like hKp10 and hKp54, along with synthetic analogs such as TAK-448 and C6, have shown promise in vivo. However, direct comparative data on the in vitro pharmacological profiles of these diverse agonists remain limited, posing a challenge for rational drug discovery and development.
Study Design
Researchers characterized and directly compared the in vitro pharmacological profiles of hKp10, hKp54, and C6. The study utilized HEK293 cells stably expressing the human Kp receptor. Primary endpoints included measuring intracellular Ca2+ mobilization over time to assess signaling kinetics and tachyphylaxis. Additionally, the expression of a selected panel of genes, including immediate-early genes, transcription factors, and inflammatory mediators, was assessed using qPCR at different time points following treatment with each agonist.
Results
The kisspeptin analog C6 produced the most sustained intracellular Ca2+ mobilization among the tested compounds. This prolonged signaling was directly associated with more pronounced tachyphylaxis, which the authors propose results from a greater depletion of intracellular Ca2+ stores. In contrast, a second stimulation with low concentrations of hKp54, but not hKp10, elicited an increased response, suggesting differential receptor desensitization mechanisms. Transcriptional analysis revealed that C6 induced the strongest and most sustained transcriptional response, followed by hKp54 and then hKp10.
Notably, marked upregulation was observed for immediate-early genes (
IER2,EGR1, andKLF10), transcription factors (NR4A1,NR4A2, andNFKB1A), and inflammatory mediators (CXCL8,CXCL1, andCCL2) following C6 treatment. These findings collectively demonstrate distinct in vitro pharmacological profiles among the three kisspeptin agonists, highlighting differences in theirKISS1Rsignaling dynamics and downstream gene regulation.
Key Findings
- C6 elicited the most sustained
intracellular Ca2+ mobilizationcompared to hKp10 and hKp54. - C6 induced more pronounced tachyphylaxis, likely due to greater
intracellular Ca2+store depletion. - C6 produced the strongest and most sustained transcriptional response among the three agonists.
- hKp54, but not hKp10, showed an increased response to a second low-concentration stimulation.
- C6 significantly upregulated immediate-early genes (
IER2,EGR1), transcription factors (NR4A1,NR4A2), and inflammatory mediators (CXCL8,CCL2).
Why It Matters
Understanding the distinct pharmacological profiles of kisspeptin agonists is crucial for optimizing their therapeutic application and minimizing adverse effects. The observed differences in Ca2+ mobilization, tachyphylaxis, and gene activation suggest that not all KISS1R agonists are created equal. For instance, an agonist like C6 with sustained signaling and robust gene activation might be potent but also prone to rapid desensitization, requiring careful dosing strategies. Conversely, agonists with less tachyphylaxis could offer more consistent long-term effects. This data provides a foundational basis for selecting lead compounds for specific clinical indications, guiding the development of more effective and safer KISS1R-targeted therapies by matching agonist properties to desired physiological outcomes and avoiding potential off-target or inflammatory responses.
kisspeptin
c6
kisspeptin-10
kisspeptin-54
gpr54
kiss1r